01—Abstract
Summary
Summary of the 8-K filed January 2, 2024. Cited figures are marked; the original filing is the authoritative source.
Laboratory Corporation of America Holdings (now Labcorp Holdings Inc.) filed this Form 8-K on January 2, 2024 under Item 7.01 (Regulation FD Disclosure) to announce that members of its executive management team will take part in a fireside chat at the 42nd Annual J.P.
Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. (PT). The filing contains no financial results, financial statements, or quantitative figures.
The company stated that a live audio webcast of the fireside chat will be available through its Investor Relations website at ir.Labcorp.com and archived for replay. The accompanying Exhibit 99.1 is a press release dated January 2, 2024, issued by Labcorp, which carries the same conference announcement. The press release describes Labcorp as a global laboratory services company serving doctors, hospitals, pharmaceutical companies, researchers and patients in over 100 countries, with more than 60,000 employees.
It also states that the company worked on over 80%a of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients. For investors, this filing is an investor-relations event notice rather than a source of new performance information.
02—Key points
Key Highlights
- Form 8-K filed January 2, 2024 under Item 7.01 (Regulation FD Disclosure) to announce a conference appearance
- Executive management team to participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 at 4:30 p.m. (PT)
- Live audio webcast available via the Company Investor Relations website at ir.Labcorp.com, with an archived replay
- Exhibit 99.1 is a press release dated January 2, 2024 announcing the conference participation
- Company describes itself as serving clients in over 100 countries with more than 60,000 employees
- Press release states the company worked on over 80% of new drugs approved by the FDA in 2022 and performed more than 600 million tests
- The filing contains no financial results or quantitative financial figures
03—Questions
Frequently Asked Questions
What is the purpose of this 8-K filing?
The filing is a Regulation FD disclosure under Item 7.01 announcing that Labcorp executive management will participate in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 at 4:30 p.m. (PT).
How can investors access the fireside chat?
A live audio webcast will be available through the Company Investor Relations website at ir.Labcorp.com, and the chat will be archived for replay on that site.
Does this filing report financial results or guidance?
No. The filing contains only the conference participation announcement and does not include financial results, financial statements, or guidance.
What does the attached Exhibit 99.1 contain?
Exhibit 99.1 is a press release dated January 2, 2024, issued by Labcorp, announcing the company's participation in the J.P. Morgan Healthcare Conference fireside chat.
Who is the company's contact for investor inquiries?
The press release lists Investor Relations contact Christin O'Donnell at 336-436-5076 and [email protected].
04—Continue